Lercadip (Lercanidipine Hydrochloride)

Lercadip, a dihydropyridine calcium channel blocker, is used to manage conditions within the hypertension disease family.

• Essential hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications.
• Isolated systolic hypertension: lowers elevated systolic pressure, improving vascular compliance.
• Secondary hypertension (when caused by vascular resistance): assists in controlling pressure when other causes are addressed.

• Lercanidipine selectively blocks L‑type calcium channels on vascular smooth‑muscle cells, inhibiting calcium influx. This causes dose‑dependent relaxation of arterial smooth muscle, leading to vasodilation, reduced peripheral resistance, and consequently lower arterial blood pressure without significant negative inotropic effects on the heart.

Lercadip may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Flushing: warmth and redness, typically occurring shortly after dosing.
• Peripheral edema: swelling of ankles or feet due to fluid accumulation.
• Dizziness: sensation of light‑headedness, especially when standing quickly.
• Fatigue: generalized tiredness without obvious cause.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure that may cause fainting.
• Angioedema: rapid swelling of face, lips, tongue, or throat requiring urgent care.
• Myocardial infarction: rare occurrence of heart attack symptoms.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Allergic reaction: rash, itching, or bronchospasm indicating hypersensitivity.

Before initiating therapy with Lercadip, several safety considerations should be observed.

• Monitor blood pressure: ensure target levels are achieved and adjust dose if needed.
• Avoid abrupt discontinuation: taper under medical supervision to prevent rebound hypertension.
• Caution in hepatic impairment: reduced metabolism may increase exposure.
• Use with caution in elderly patients: increased sensitivity to vasodilatory effects.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercadip can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise plasma concentrations and increase risk of hypotension.
• Co‑administration with other potent antihypertensives (e.g., ACE inhibitors, beta‑blockers): can cause additive blood‑pressure lowering effects.
• Grapefruit juice: can inhibit metabolism and elevate drug levels.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase risk of renal impairment.
• Diuretics: may enhance hypotensive response, requiring closer blood‑pressure monitoring.